Höfer R
Abteilung für Nuklearmedizin, II. Medizinischen Universitätsklinik Wien.
Acta Med Austriaca. 1987;14(3-4):70-2.
The present state of knowledge of the patho-etiology of autoimmune-hyperthyroidism (Graves' disease) enables us to design a therapeutic strategy basing on causal events of the autoimmune disease and aiming at complete restoration, considering the pros and cons of conservative (antithyroid drug) and destructive (surgery and/or radioactive iodine) therapy. Summarizing the arguments it is stated that antithyroid drugs are the therapy of first choice in Graves' disease, there are, however, no parameters available to predict firmly relapse in hyperthyroid Graves' disease and to establish duration of antithyroid drug treatment. For patients with hyperthyroid Graves' disease recurring after long term antithyroid drug treatment ablation of the thyroid gland as target organ of the autoimmune disease is advocated; requirements for this decision are discussed.
自身免疫性甲状腺功能亢进症(格雷夫斯病)的病理病因学的当前知识状态,使我们能够基于自身免疫性疾病的因果事件设计一种治疗策略,旨在实现完全恢复,同时考虑保守治疗(抗甲状腺药物)和破坏性治疗(手术和/或放射性碘)的利弊。总结相关论点可知,抗甲状腺药物是格雷夫斯病的首选治疗方法,然而,目前尚无参数可用于准确预测甲状腺功能亢进型格雷夫斯病的复发情况以及确定抗甲状腺药物治疗的持续时间。对于长期接受抗甲状腺药物治疗后复发的甲状腺功能亢进型格雷夫斯病患者,主张将甲状腺作为自身免疫性疾病的靶器官进行消融;文中讨论了做出这一决定的要求。